COVID-19 and the Cardiovascular System.

Szczegóły
Abstrakt

Tytuł:: COVID-19 and the Cardiovascular System.
Autorzy:: Veer M; Cardiovascular Institute, Allegheny Health Network, Allegheny General Hospital, Pittsburgh, Pennsylvania.
Kumar AM
Ivanova V
Źródło:: Critical care nursing quarterly [Crit Care Nurs Q] 2020 Oct/Dec; Vol. 43 (4), pp. 381-389.
Typ publikacji:: Journal Article; Review
Język:: English
Imprint Name(s):: Publication: 2003- : Hagerstown, MD : Lippincott Williams & Wilkins
Original Publication: [Frederick, Md. : Aspen Publishers, c1987-
MeSH Terms:: Cardiovascular Diseases/*therapy
Cardiovascular Diseases/*virology
Coronavirus Infections/*complications
Coronavirus Infections/*therapy
Pneumonia, Viral/*complications
Pneumonia, Viral/*therapy
COVID-19 ; Cardiovascular Diseases/epidemiology ; Clinical Trials as Topic ; Coronavirus Infections/epidemiology ; Humans ; Pandemics ; Pneumonia, Viral/epidemiology
References:: Atri D, Siddiqi HK, Lang J, Nauffal V, Morrow DA, Bohula EA. COVID-19 for the cardiologist: a current review of the virology, clinical epidemiology, cardiac and other clinical manifestations and potential therapeutic strategies. JACC Basic Transl Sci. 2020. doi:10.1016/j.jacbts.2020.04.002.
Li R, Pei S, Chen B, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). Science. 2020;368(6490):489–493. doi:10.1126/science.abb3221.
Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic transmission of SARS-CoV-2—Singapore, January 23-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(14):411–415.
Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323(18):1843–1844.
Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med. 2020;46(5):854–887.
NYC Health. COVID-19: data. https://www1.nyc.gov/site/doh/covid/covid-19-data.page. Accessed April 15, 2020.
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720.
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020:e200994. doi:10.1001/jamainternmed.2020.0994.
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069.
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513.
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846–848.
Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020:e201017. doi:10.1001/jamacardio.2020.1017.
Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with covid-19 in Wuhan, China. JAMA Cardiol. 2020:e200950. doi:10.1001/jamacardio.2020.0950.
Courand PY, Harbaoui B, Bonnet M, Lantelme P. Spontaneous coronary artery dissection in a patient with COVID-19. JACC: Cardiovasc Interv. 2020. doi:10.1002/ccd.28960.
Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin. Eur Heart J. 2020:ehaa190.
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020:181(2):271–280.e8.
Brosnihan KB, Neves LAA, Chappell MC. Does the angiotensin-converting enzyme (ACE)/ACE2 balance contribute to the fate of angiotensin peptides in programmed hypertension? Hypertension. 2005;46(5):1097–1099.
Tikellis C, Thomas MC. Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease. Int J Pept. 2012;2012:256294.
Hamming I, Cooper ME, Haagmans BL, et al. The emerging role of ACE2 in physiology and disease. J Pathol. 2007;212(1):1–11.
Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277(17):14838–14843.
Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470–473.
Guo J, Huang Z, Lin L, Lv J. Coronavirus disease 2019 (COVID-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection. J Am Heart Assoc. 2020;9(7):e016219.
Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382(17):1653–1659. doi:10.1056/NEJMsr2005760.
HFSA/ACC/AHA. HFSA/ACC/AHA statement addres-ses concerns re: using RAAS antagonists in COVID-19. https://professional.heart.org/professional/ScienceNews/UCM_505836_HFSAACCAHAstatement-addresses-concerns-re-using-RAAS-antagonists-in-COVID.jsp. Updated March 17, 2020. Accessed April 15, 2020.
Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol. 2020;75(18):2352–2371.
Garcia S, Albaghdadi MS, Meraj PM, et al. Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic. J Am Coll Cardiol. 2020;S0735-1097(20):34913–34915.
Udell JA, Zawi R, Bhatt DL, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA. 2013;310(16):1711–1720.
Kwong JC, Schwartz KL, Campitelli MA. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med. 2018;378(26):2540–2541.
Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020. doi:10.1001/jamacardio.2020.1096.
Welt FGP, Shah PB, Aronow HD, et al. Catheterization laboratory considerations during the coronavirus (COVID-19) pandemic: from ACC's Interventional Council and SCAI. J Am Coll Cardiol. 2020;75(18):27191.
Lazzerini PE, Boutjdir M, Capecchi PL. COVID-19, arrhythmias and inflammation: mind the gap! Circulation. 2020. doi:10.1161/CIRCULATIONAHA.120.047293.
Wu CI, Postema PG, Arbelo E, et al. SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes. Heart Rhythm. 2020;S1547-5271(20):30285–X.
Food and Drug Administration. Fact Sheet for Health Care Providers Emergency USE Authorization (EUA) of Hydroxychloroquine Sulfate Supplied From the Strategic National Stockpile for Treatment of COVID-19 in Certain Hospitalized Patients. Silver Spring, MD: Food and Drug Administration; 2020.
Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19). Mayo Clin Proc. 2020. doi:10.1016/j.mayocp.2020.03.024.
Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for drug interactions on QTc in exploratory COVID-19 (coronavirus disease 2019) treatment. Circulation. 2020. doi:10.1161/CIRCULATIONAHA.120.047521.
Tisdale J, Wroblewski HA, Kingery JR, Trujillo TN, Overholser BR, Kovacs RJ. A risk score to predict QT interval prolongation in hospitalized patients. J Am Coll Cardiol. 2011;57(14)(suppl):E112.
Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479–487.
Simpson T, Kovacs RJ, Stecker E. Ventricular arrhythmia risk due to hydroxychloroquine-azithromycin treatment for COVID-19. Cardiology Magazine. March 29, 2020. https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19. Accessed June 9, 2020.
Entry Date(s):: Date Created: 20200825 Date Completed: 20200828 Latest Revision: 20210121
Update Code:: 20240105
DOI:: 10.1097/CNQ.0000000000000323
PMID:: 32833774
: Czasopismo naukowe

COVID-19, a symptom complex of respiratory failure induced by a highly infectious pathogen, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has been classified as a pandemic. As of April 15, 2020, there have been 2 million people diagnosed with the viral infection and 130 000 deaths globally. It is highly likely that the number of infections is underrepresented secondary to variations in testing and reporting strategies globally. In this short review, we aim to summarize the current understanding of SARS-CoV-2 as it pertains to cardiovascular disease. We discuss the basis of cardiac pathophysiology and address some of the clinical scenarios that cardiovascular physicians may face. We introduce the concept of conservative management of acute coronary syndromes and address some complications such as myocarditis, heart failure, and cardiac arrhythmias that may be relevant for the management of patients presenting with COVID-19.

Informacja